Progyny, Inc. (NASDAQ:PGNY) Receives Average Rating of “Hold” from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNYGet Free Report) have earned a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $25.42.

PGNY has been the topic of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, September 19th. Leerink Partners cut their price objective on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a report on Thursday, September 19th. Barclays lowered their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday. Canaccord Genuity Group cut their price target on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday. Finally, Jefferies Financial Group reduced their price target on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th.

Get Our Latest Research Report on Progyny

Institutional Investors Weigh In On Progyny

Several large investors have recently modified their holdings of PGNY. Quarry LP lifted its holdings in shares of Progyny by 1,900.0% during the 2nd quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after purchasing an additional 836 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Progyny in the second quarter valued at approximately $44,000. Mendota Financial Group LLC acquired a new position in shares of Progyny in the third quarter valued at approximately $56,000. Meeder Asset Management Inc. acquired a new position in shares of Progyny in the third quarter valued at approximately $77,000. Finally, Cambridge Trust Co. bought a new stake in shares of Progyny during the first quarter worth $95,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Price Performance

PGNY stock opened at $13.98 on Friday. The company has a 50 day moving average price of $17.49 and a 200 day moving average price of $23.49. Progyny has a fifty-two week low of $13.77 and a fifty-two week high of $42.08. The stock has a market capitalization of $1.26 billion, a PE ratio of 24.10, a price-to-earnings-growth ratio of 1.62 and a beta of 1.44.

Progyny (NASDAQ:PGNYGet Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 10.87% and a net margin of 5.03%. The firm had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same quarter in the previous year, the firm earned $0.16 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. As a group, equities analysts expect that Progyny will post 0.64 earnings per share for the current fiscal year.

Progyny Company Profile

(Get Free Report

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also

Analyst Recommendations for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.